

Supporting Information

Bioreducible polymers as a determining factor for polyplex decomplexation rate and transfection

Hee Sook Hwang^{†,‡}, Han Chang Kang^{‡,§}, You Han Bae^{†,#,*}

[†] Department of Pharmaceutics and Pharmaceutical Chemistry, The University of Utah, 421 Wakara Way, Suite 318, Salt Lake City, Utah 84108, USA

[§] Department of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 420-743, Republic of Korea

[#] Utah-Inha Drug Delivery Systems (DDS) and Advanced Therapeutics Research Center, 7-50 Songdo-dong, Yeonsu-gu, Incheon, 406-840, Republic of Korea

[‡] HSH and HCK equally contributed to this work.

* Correspondence to:

Professor You Han Bae, Ph.D., Department of Pharmaceutics and Pharmaceutical Chemistry, The University of Utah, 421 Wakara Way, Suite 318, Salt Lake City, Utah 84108, USA.

Tel: +1-801-585-1518; Fax: +1-801-585-3614.

E-mail address: you.bae@utah.edu




Figure S1. Synthetic scheme of reducible poly(Cys-Lys₈-Cys) (RPLL)




Figure S2. $^1\text{H-NMR}$ analysis of RPLL in D_2O




Figure S3. Condensation of pDNA with either PLL or RPLL in agarose gel





Figure S4. Normalized Transfection efficiencies of PLL_{100-x}RPLL_x/pDNA complexes (PRL_x polyplexes) (N/P 5) in MCF7 cells and HEK293 cells. PLL/pDNA and RPLL/pDNA complexes were denominated as PRL₀ and PRL₁₀₀ polyplexes, respectively. Transfection efficiency of PRL₁₀₀ polyplexes was set as a unity. ** p<0.01 vs. PRL₁₀₀ polyplex (Mean ± Standard Error; n ≥ 4)





Figure S5. Dose-dependent cytotoxicity of PLL and RPLL in MCF7 and HEK293 cells. The cells were exposed to the polymers for 24 hr in the serum-containing medium. (Mean \pm Standard Error; n = 6)